



> Loïc Bureau,
Professeur Associé,
UFR des sciences
pharmaceutiques et
biologiques, Université
Rennes-1 IFAS, Le Mans

Le cannabidiol : récepteurs et propriétés

BIBLIOGRAPHIE

- [39] Alsherbiny MA, Bhuyan DJ, Low MN, Chang D, Li CG. Synergistic Interactions of Cannabidiol with Chemotherapeutic Drugs in MCF7 Cells: Mode of Interaction and Proteomics Analysis of Mechanisms, *Int J Mol Sci*. 2021 Sep 18;22(18):10103.
- [33] Atalay S, Jarocka-Karpowicz I, Skrzydlewska E. Antioxidative and Anti-Inflammatory Properties of Cannabidiol, Antioxidants (Basel). 2019 Dec 25;9(1):21.
- [26] Bakas T, van Nieuwenhuijzen PS, Devenish SO, McGregor IS, Arnold JC, Chebib M. The direct actions of cannabidiol and 2-arachidonoyl glycerol at GABAA receptors, *Pharmacol Res*. 2017 May;119:358-370.
- [46] Bass J, Linz DR. A Case of Toxicity from Cannabidiol Gummy Ingestion, *Cureus*. 2020 Apr 16;12(4):e7688.
- [43] Berger BA, Stolz U, Colvin J, Otten EJ. Epidemiology of cannabidiol related cases reported in the National Poison Data System - 2019-2020, *Am J Emerg Med*. 2021 Oct;48:218-223.
- [51] Bhamra SK, Desai A, Imani-Berendjestanki P, Horgan M. The emerging role of cannabidiol (CBD) products; a survey exploring the public's use and perceptions of CBD, *Phytother Res*. 2021 Oct;35(10):5734-5740.
- [27] Bielawiec P, Harasim-Symbor E, Sztolsztener K, Konstantynowicz-Nowicka K, Chabowski A. Attenuation of Oxidative Stress and Inflammatory Response by Chronic Cannabidiol Administration Is Associated with Improved n-6/n-3 PUFA Ratio in the White and Red Skeletal Muscle in a Rat Model of High-Fat Diet-Induced Obesity, *Nutrients*. 2021 May 11;13(5):1603.
- [17] Bielawiec P, Harasim-Symbor E, Chabowski A. Phytocannabinoids: Useful Drugs for the Treatment of Obesity? Special Focus on Cannabidiol, *Front Endocrinol (Lausanne)*. 2020 Mar 4;11:114.
- [29] Blessing EM, Steenkamp MM, Manzanarez J, Marmar CR. Cannabidiol as a Potential Treatment for Anxiety Disorders, *Neurotherapeutics*. 2015 Oct;12(4):825-36.
- [14] Bonaccorso S, Ricciardi A, Zangani C, Chiappini S, Schifano F. Cannabidiol (CBD) use in psychiatric disorders: A systematic review, *Neurotoxicology*. 2019 Sep;74:282-298.
- [53] Britch SC, Babalonis S, Walsh SL. ? Cannabidiol: pharmacology and therapeutic targets ? *Psychopharmacology (Berl)*. 2021 Jan;238(1):9-28.
- [25] Cassano T, Villani R, Pace L, Carbone A, Bukke VN, Orkisz S, Avolio C, Serviddio G. From Cannabis sativa to Cannabidiol: Promising Therapeutic Candidate for the Treatment of Neurodegenerative Diseases, *Front Pharmacol*. 2020 Mar 6;11:124.
- [9] Chanda D, Neumann D, Glatz JFC. The endocannabinoid system: Overview of an emerging multi-faceted therapeutic target, *Prostaglandins Leukot Essent Fatty Acids*. 2019 Jan;140:51-56.
- [41] Chesney E, Oliver D, Green A, Sovi S, Wilson J, Englund A, Freeman TP, McGuire P. Adverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials, *Neuropsychopharmacology*. 2020 Oct;45(11):1799-1806.
- [57] Cogan PS. Reality and Legality: Disentangling What Is Actual from What Is Tolerated in Comparisons of Hemp Extracts with Pure CBD, *J Diet Suppl*. 2020;17(5):527-542.
- [2] Corroon J, Felice JF. The Endocannabinoid System and its Modulation by Cannabidiol (CBD), *Altern Ther Health Med*. 2019 Jun;25(S2):6-14.
- [41] Dos Santos RG, Guimarães FS, Crippa JAS, Hallak JEC, Rossi GN, Rocha JM, Zuardi AW. Serious adverse effects of cannabidiol (CBD): a review of randomized controlled trials ? *Expert Opin Drug Metab Toxicol*. 2020 Jun;16(6):517-526.
- [30] Franco V, Bialer M, Perucca E. Cannabidiol in the treatment of epilepsy: Current evidence and perspectives for further research, *Neuropharmacology*. 2021 Mar 1;185:108442.
- [11] Gado F, Meini S, Bertini S, Digiacomo M, Macchia M, Manera C. Allosteric modulators targeting cannabinoid cb1 and cb2 receptors: implications for drug discovery, *Future Med Chem*. 2019 Aug;11(15):2019-2037.
- [45] Golombek P, Müller M, Barthlott I, Sproll C, Lachenmeier DW. Conversion of Cannabidiol (CBD) into Psychotropic Cannabinoids Including Tetrahydrocannabinol (THC): A Controversy in the Scientific Literature, *Toxics*. 2020 Jun 3;8(2):41.
- [31] Golub V, Reddy DS. Cannabidiol Therapy for Refractory Epilepsy and Seizure Disorders, *Adv Exp Med Biol*. 2021;1264:93-110.
- [49] Hahn B. The Potential of Cannabidiol Treatment for Cannabis Users With Recent-Onset Psychosis, *Schizophr Bull*. 2018 Jan 13;44(1):46-53.
- [22] Hashiesh HM, Sharma C, Goyal SN, Jha NK, Ojha S. Pharmacological Properties, Therapeutic Potential and Molecular Mechanisms of JWH133, a CB2 Receptor-Selective Agonist, *Front Pharmacol*. 2021 Jul 30;12:702675.
- [7] Howlett AC, Abood ME. CB1 and CB2 Receptor Pharmacology, *Adv Pharmacol*. 2017;80:169-206.
- [40] Huestis MA, Solimini R, Pichini S, Pacifici R, Carlier J, Busardò FP. Cannabidiol Adverse Effects and Toxicity, *Curr Neuropharmacol*. 2019;17(10):974-989.
- [23] Jakowiecki J, Abel R, Orzeł U, Pasznik P, Preissner R, Filipiek S. Allosteric Modulation of the CB1 Cannabinoid Receptor by Cannabidiol-A Molecular Modeling Study of the N-Terminal Domain and the Allosteric-Orthosteric Coupling, *Molecules*. 2021 Apr 23;26(9):2456.
- [56] Koturbash I, MacKay D. Cannabidiol and Other Cannabinoids: From Toxicology and Pharmacology to the Development of a Regulatory Pathway, *J Diet Suppl*. 2020;17(5):487-492.
- [42] Lachenmeier DW, Walch SG. Evidence for adverse effects of cannabidiol (CBD) products and their non-conformity on the European food market - response to the European Industrial Hemp Association, *Food Res*. 2020 Aug 26;9:1051.
- [1] Ligresti A, De Petrocellis L, Di Marzo V. From Phytocannabinoids to Cannabinoid Receptors and Endocannabinoids: Pleiotropic Physiological and Pathological Roles Through Complex Pharmacology, *Physiol Rev*. 2016 Oct;96(4):1593-659.
- [35] Likar R, Köstenberger M, Nahler G. Cannabidiol in cancer treatment, *Schmerz*. 2020 Apr;34(2):117-122.
- [3] Lowe H, Toyang N, Steele B, Bryant J, Ngwa W. The Endocannabinoid System: A Potential Target for the Treatment of Various Diseases, *Int J Mol Sci*. 2021 Aug 31;22(17):9472.
- [47] Madera-Acosta A, Johnson-Wall H, Carbone LD, Meszaros A, Berman AE, White J. Cannabidiol (CBD) oil toxicity mimicking extraglandular complications of Sjogren's syndrome, *Rheumatol Adv Pract*. 2021 Feb 27;5(1):rkab010.
- [5] Maia J, Fonseca BM, Teixeira N, Correia-da-Silva G. The fundamental role of the endocannabinoid system in endometrium and placenta: implications in pathophysiological aspects of uterine and pregnancy disorders, *Hum Reprod Update*. 2020 Jun 18;26(4):586-602.
- [54] Marinotti O, Sarill M. Differentiating Full-Spectrum Hemp Extracts from CBD Isolates: Implications for Policy, Safety and Science, *J Diet Suppl*. 2020;17(5):517-526.
- [50] Millar SA, Maguire RF, Yates AS, O'Sullivan SE. Towards Better Delivery of Cannabidiol (CBD), *Pharmaceuticals (Basel)*. 2020 Aug 28;13(9):219.



- [19] Mlost J, Bryk M, Starowicz K., Cannabidiol for Pain Treatment: Focus on Pharmacology and Mechanism of Action, *Int J Mol Sci.* 2020 Nov 23;21(22):8870.
- [13] Morales P, Hernandez-Folgado L, Goya P, Jagerovic N. Cannabinoid receptor 2 (CB2) agonists and antagonists: a patent update., *Expert Opin Ther Pat.* 2016 Jul;26(7):843-56.
- [15] Morales P, Hurst DP, Reggio PH, Molecular Targets of the Phytocannabinoids: A Complex Picture, *Prog Chem Org Nat Prod.* 2017; 103:103-131.
- [25] Morales P, Goya P, Jagerovic N., Emerging strategies targeting CB2 cannabinoid receptor: Biased agonism and allosterism, *Biochem Pharmacol.* 2018 Nov;157:8-17.
- [8] Navarro G, Varani K, Lillo A, Vincenzi F, Rivas-Santisteban R, Raich I, Reyes-Resina I, Ferreiro-Vera C, Borea PA, Sánchez de Medina V, Nadal X, Franco R., Pharmacological data of cannabidiol- and cannabigerol-type phytocannabinoids acting on cannabinoid CB1, CB2 and CB1/CB2 heteromer receptors, *Pharmacol Res.* 2020 Sep;159:104940.
- [18] Newton M, Newton DW. Cannabidiol or CBD Oil: Help, Hope, and Hype for Psychiatric and Neurologic Conditions, *J Am Psychiatr Nurses Assoc.* 2020 Sep/Oct;26(5):447-457.
- [34] Pereira SR, Hackett B, O'Driscoll DN, Sun MC, Downer EJ. Cannabidiol modulation of oxidative stress and signalling, *Neuronal Signal.* 2021 Aug 24;5(3):NS20200080.
- [16] Pisanti S, Malfitano AM, Ciaglia E, Lamberti A, Ranieri R, Cuomo G, Abate M, Faggiana G, Proto MC, Fiore D, Laezza C, Bifulco M. Cannabidiol: State of the art and new challenges for therapeutic applications, *Pharmacol Ther.* 2017 Jul;175:133-150.
- [52] Raup-Konsavage WM, Carkaci-Salli N, Greenland K, Gearhart R, Vrana KE, Cannabidiol (CBD) Oil Does Not Display an Entourage Effect in Reducing Cancer Cell Viability in vitro, *Med Cannabis Cannabinoids.* 2020 Sep 17;3(2):95-102.
- [12] Riether D. Selective cannabinoid receptor 2 modulators: a patent review 2009--present, *Expert Opin Ther Pat.* 2012 May;22(5):495-510.
- [48] Schoedel KA, Szeto I, Setnik B, Sellers EM, Levy-Cooperman N, Mills C, Etges T, Sommerville K. Abuse potential assessment of cannabidiol (CBD) in recreational polydrug users: A randomized, double-blind, controlled trial ? *Epilepsy Behav.* 2018 Nov;88:162-171.
- [10] Sebag JA., et Pantel J., Ciblage thérapeutique des récepteurs couplés aux protéines G, La voie allostérique, *Med Sci (Paris),* 2012, 28 (10), P.845 – 851.
- [36] Seltzer ES, Watters AK, MacKenzie D Jr, Granat LM, Zhang D, Cannabidiol (CBD) as a Promising Anti-Cancer Drug, *Cancers (Basel).* 2020 Oct 30;12(11):3203.
- [32] Slomski A. Cannabidiol May Help Normalize Brain Function in Psychosis, *JAMA.* 2019 Jan 29;321(4):335.
- [6] Stasiulewicz A, Znajdek K, Grudzień M, Pawiński T, Sulkowska AJL. A Guide to Targeting the Endocannabinoid System in Drug Design, *Int J Mol Sci.* 2020 Apr 16;21(8):2778.
- [28] Szabó IL, Lisztes E, Béke G, Tóth KF, Paus R, Oláh A, Bíró T., The Phytocannabinoid (-)-Cannabidiol Operates as a Complex, Differential Modulator of Human Hair Growth: Anti-Inflammatory Submicromolar versus Hair Growth Inhibitory Micromolar Effects, *J Invest Dermatol.* 2020 Feb;140(2):484-488.e5.
- [21] Tham M, Yilmaz O, Alaverdashvili M, Kelly MEM, Denovan-Wright EM, Laprairie RB. Allosteric and orthosteric pharmacology of cannabidiol and cannabidiol-dimethylheptyl at the type 1 and type 2 cannabinoid receptors, *Br J Pharmacol.* 2019 May;176(10):1455-1469.
- [20] Turner SE, Williams CM, Iversen L, Whalley BJ., Molecular Pharmacology of Phytocannabinoids, *Prog Chem Org Nat Prod.* 2017;103:61-101.
- [38] Urits I, Gress K, Charipova K, Habib K, Lee D, Lee C, Jung JW, Kassem H, Cornett E, Paladini A, Varrassi G, Kaye AD, Viswanath O., Use of cannabidiol (CBD) for the treatment of chronic pain, *Best Pract Res Clin Anaesthesiol.* 2020 Sep;34(3):463-477.
- [44] Vodovar D, Caré W, Dufayet L, Batisse A. Cannabidiol-induced toxicity: who is the culprit? *Am J Emerg Med.* 2021 Sep;47:284-285.
- [4] Wilkerson JL, Bilbrey JA, Felix JS, Makriyannis A, McMahon LR, Untapped endocannabinoid pharmacological targets: Pipe dream or pipeline? *Pharmacol Biochem Behav.* 2021 Jul;206:173192.
- [55] Wu J. Cannabis, cannabinoid receptors, and endocannabinoid system: yesterday, today, and tomorrow, *Acta Pharmacol Sin.* 2019 Mar;40(3):297-299.
- [59] Braille M, Marcella S, Marone G, Galdiero MR, Varricchi G, Loffredo S ? The Interplay between the Immune and the Endocannabinoid Systems in Cancer ? *Cells.* 2021 May 21;10(6):1282.
- [60] Di Marzo V, Piscitelli F, The Endocannabinoid System and its Modulation by Phytocannabinoids ? *Neurotherapeutics.* 2015 Oct;12(4):692-8.